NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma

CONCLUSION: The observation that this missense mutation of NOTCH3 is associated with an increased response to treatment with gemcitabine in EHE can be used prospectively to assess NOTCH3 as potential biomarker for predicting therapy response to gemcitabine.PMID:36749424 | DOI:10.1007/s00432-023-04598-1

Source: Clin Med Res - February 7, 2023 Category: Research Authors: Moritz Schmidt Sven Mattern Stephan Singer Martin Schulze Saskia Biskup Patrick Krumm Ulrich M Lauer Lars Zender Clemens Hinterleitner Martina Hinterleitner Source Type: research